

Davidson, Mark

From: Davidson, Mark
Sent: Thursday, June 29, 2017 8:48 AM
To: 'Rizwana Sproule'
Cc: 'Nadia Agopyan'; 'Alex Babayan'
Subject: BLA 125643 -YESCARTA® Proprietary Name Acceptance

Importance: High

Dear Dr. Sproule:

We have reviewed your March 31, 2017, submission to your Biologics License Application (BLA) for axicabtagene ciloleucel, requesting a proprietary name review for YESCARTA®.

In consultation with Center for Biologics Evaluation and Research's Advertising and Promotional Labeling Branch (CBER/APLB), we conclude that, under the Federal Food, Drug, and Cosmetic Act and applicable regulations, YESCARTA® is Acceptable.

If you have any questions, please contact the Regulatory Project Manager, Mark L. Davidson at (240) 402-8277.

Sincerely yours,

Mark L. Davidson, RHIA
Regulatory Project Manager
OTAT/CBER/FDA
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 240-402-8277
Fax: 301-595-1303
mark.davidson@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."